Table 2

Crude incidence rates* of SARS-CoV-2 infection, COVID-19 hospitalisation, and COVID-19 mortality by IBD medication group and corticosteroid use

Person-timeFailures†Incidence rate*95% CI
 COVID-19 infectionIBD medication category
Mesalazine133 99424718.4316.27 to 20.88
Thiopurine24 3864920.0915.19 to 26.59
Anti-TNF41 8429522.7018.57 to 27.76
Anti-TNF+TP12 5493326.3018.69 to 36.99
Anti-TNF+MTX53891018.569.98 to 34.49
Vedolizumab89783134.5324.28 to 49.10
Ustekinumab1760422.738.53 to 60.57
Tofacitinib793225.226.31 to 100.83
No IBD Meds93 71218419.6316.99 to 22.69
Corticosteroid use
No301 97358819.4717.96 to 21.11
Yes18 8766132.3225.14 to 41.53
 COVID-19 hospitalisationIBD medication category
Mesalazine134 015402.982.19 to 4.07
Thiopurine24 390104.102.21 to 7.62
Anti-TNF41 859133.111.80 to 5.35
Anti-TNF+TP12 54975.582.66 to 11.70
Anti-TNF+MTX539047.422.79 to 19.77
Vedolizumab898666.683.00 to 14.86
Ustekinumab175915.680.80 to 40.35
Tofacitinib79300
No IBD Meds93 740454.803.58 to 6.43
Corticosteroid use
No302 0461083.582.96 to 4.32
Yes18 883179.005.60 to 14.48
 COVID-19 mortalityIBD medication category
Mesalazine4 078 807230.060.04 to 0.08
Thiopurine742 29120.030.01 to 0.11
Anti-TNF1 273 56500.00
Anti-TNF+TP381 97910.030.00 to 0.19
Anti-TNF+MTX164 03900.00
Vedolizumab273 29110.040.01 to 0.26
Ustekinumab53 56000.00
Tofacitinib24 13900.00
No IBD Meds2 852 623140.050.03 to 0.08
Corticosteroid use
No9 253 594400.040.03 to 0.06
Yes590 70010.020.00 to 0.12
  • *Reported per 10 000 person-months.

  • † ‘Failures’ refers to infections in the first portion of the table, hospitalisations in the second portion of the table, and mortality in the third portion of the table.

  • IBD, inflammatory bowel disease; MTX, methotrexate; TNF, tumour necrosis factor; TP, thiopurine.